Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Add as a preferred source on Google
RALEIGH, N.C., March 07, 2018 -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2017, after the market close, and will host a conference call and webcast on Thursday, March 15, 2018, at 4:30 PM Eastern Time.
Conference Call & Webcast
Thursday, March 15th @ 4:30pm Eastern Time
| Domestic: | 866-548-4713 |
| International: | 323-794-2093 |
| Passcode: | 6437809 |
| Webcast: | http://public.viavid.com/index.php?id=128377 |
Replays available through March 29:
| Domestic: | 844-512-2921 |
| International: | 412-317-6671 |
| Conference ID: | 6437809 |
About BioDelivery Sciences International, Inc.
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain and opioid dependence. BDSI's headquarters is in Raleigh, North Carolina.
For more information, please visit or follow us:
| Internet: | www.bdsi.com |
| Facebook: | Facebook.com/BioDeliverySI |
| Twitter: | @BioDeliverySI |
BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) and BELBUCA® (buprenorphine) buccal film (CIII) are marketed in the U.S. by BioDelivery Sciences. For full prescribing information and important safety information on BDSI products please visit www.bdsi.com where the Company promptly posts press releases, SEC filings and other important information or contact the Company at (800) 469-0261. For full prescribing and safety information on BELBUCA, please visit www.belbuca.com and for full prescribing and safety information on BUNAVAIL, please visit www.bunavail.com.
Cautionary Note on Forward-Looking Statements
This press release, the presentation described herein, and any statements of employees, representatives and partners of BioDelivery Sciences International, Inc. ("BDSI") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the BDSI's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the BDSI's management and are subject to significant risks and uncertainties, including those detailed in the BDSI's filings with the Securities and Exchange Commission. Actual results (including, without limitation, the results of the Company’s commercialization programs for BELBUCA, BUNAVAIL and ONSOLIS) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the BDSI's control). BDSI undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
BDSI®, BEMA®, ONSOLIS®, BUNAVAIL® and BELBUCA® are registered trademarks of BioDelivery Sciences International, Inc. The BioDelivery Sciences, BUNAVAIL and BELBUCA logos are trademarks owned by BioDelivery Sciences International, Inc. All other trademarks and tradenames are owned by their respective owners.
© 2018 BioDelivery Sciences International, Inc. All rights reserved.
Contacts
Investors:
Al Medwar
Senior Vice President, Corporate and Business Development
BioDelivery Sciences International, Inc.
919-582-9050
[email protected]
Monique Kosse
Managing Director
LifeSci Advisors
212-915-3820
[email protected]
